pharma

ASCO: Whose Presentations Look the Most Promising?

So called "analysts" are just spin-artists.

Kras data are extremely important since Kras-status will identify cancer patients who will greatly benefit from using EGFr drugs specifically Erbitux from ImClone.

Erbitux is a very expensive drug but it offers to select head & neck, lung and colorectal cancer patients substantial survival benefits, improved quality of life, and for some patients cancer-free survival and even a cure.

Knowing the Kras-status, physicians will be very much eager offering Erbitux to patients who will DEFINITELY benefit from it. This will establish Erbitux as a standard of care for these patients.

This will make Erbitux a mega-blockbuster. Note that Erbitux's worldwide sale is already over $1.5B.